Publications
Recently Published
- Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle. Vaccines (Basel). 2021 Nov 17;9(11):1347. doi: 10.3390/vaccines9111347. PMID: 34835278; PMCID: PMC8619098.
- Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug Resistant Pseudomonas aeruginosa Murine Model. Antibiotics (Basel). 2021 Aug 5;10(8):946. doi: 10.3390/antibiotics10080946. PMID: 34438996; PMCID: PMC8388862.
- Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia. Open Forum Infect Dis. 2020 Jun 19;7(8):ofaa236. doi: 10.1093/ofid/ofaa236. PMID: 32766380; PMCID: PMC7397834.
- CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology. Vaccines (Basel). 2021 Nov 17;9(11):1346. doi: 10.3390/vaccines9111346. PMID: 34835277; PMCID: PMC8618284.
- Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 Aug 20;373(6557):931-936. doi: 10.1126/science.abg5827. Epub 2021 Jul 20. PMID: 34285133.